Last Updated : March 5, 2025
Details
FilesGeneric Name:
durvalumab
Project Status:
Active
Therapeutic Area:
limited-stage small cell lung cancer (LS-SCLC)
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Imfinzi
Project Line:
Reimbursement Review
Project Number:
PC0389-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Imfinzi (durvalumab) is currently under review by Health Canada for the following proposed indication: for the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Imfinzi (durvalumab) is currently under review by Health Canada for the following proposed indication: for the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 02-Oct-24 |
|---|---|
| Call for patient/clinician input closed | 25-Nov-24 |
| Submission received | 15-Nov-24 |
| Submission accepted | 29-Nov-24 |
| Review initiated | 02-Dec-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 24-Feb-25 |
| Deadline for sponsors comments | 05-Mar-25 |
| CADTH review report(s) and responses to comments provided to sponsor | 28-Mar-25 |
| Expert committee meeting (initial) | 09-Apr-25 |
| Draft recommendation issued to sponsor | April 23, 2025 To April 25, 2025 |
| Draft recommendation posted for stakeholder feedback | 01-May-25 |
| End of feedback period | 15-May-25 |
Files
Last Updated : March 5, 2025